0000899243-21-044427.txt : 20211112 0000899243-21-044427.hdr.sgml : 20211112 20211112173137 ACCESSION NUMBER: 0000899243-21-044427 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211110 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEVIN MARK J CENTRAL INDEX KEY: 0001180428 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 211405081 MAIL ADDRESS: STREET 1: 29 NEWBURY STREET STREET 2: 3RD FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-10 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001180428 LEVIN MARK J C/O THIRD ROCK VENTURES, LLC, 29 NEWBURY STREET, 3RD FLOOR BOSTON MA 02116 1 0 1 0 Common Stock 2021-11-10 4 J 0 1000000 D 3962202 I See footnote Common Stock 0 I See footnote Common Stock 75800 D Common Stock 8423 I See footnote Pursuant to a 10b5-1 trading plan adopted on September 8, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on November 10, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. The Reporting Person is a partner of TRV GP III, which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Third Rock Ventures IV, L.P. ("TRV IV") directly holds 2,343,154 shares. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. TRV III and TRV IV disclaim the existence of a Section 13(d) "group" as between any TRV III related parties and any TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. The shares are directly held by the Reporting Person. Includes Shares received in the distributions described in footnote (1) above. The shares are directly held by the Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above. /s/ Mark Levin 2021-11-12